Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenap
<p style="text-align:justify">Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of <em>non-small cell lung cancer (</em>NSCLC)<em>. </em> And in an early parallel study in humans, combining immunotherapy with dupilumab<em>—</em>an <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2018.00888/full" target=" blank">Interleukin-4</a> (IL-4) receptor-blocking antibody widely used for treating allergies and asthma<em>—</em>boosted patients' immune systems, with one out of the six experiencing significant tumor reduction. The findings were described in the December 6 issue of<em> Nature.</em></p>
Renal HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells which play a key role in immune response that eradicated tumors and prevented their recurrence in mouse models of melanoma.